Effect of Cyclooxygenase Activity on Amyloid

About the Research Project
Program
Award Type
Standard
Award Amount
$500,000
Active Dates
August 01, 2004 - July 31, 2007
Grant ID
A2004517
Summary
This study focuses on the effects of an enzyme, cyclo-oxygenase, on amyloid beta, the protein fragment that aggregates into plaques in the brains of Alzheimer’s patients. The process by which amyloid beta accumulates and clumps together to create plaques is not well understood, but scientists think it is central to the development of Alzheimer’s disease. The study may shed light on how non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen are thought to lower the risk of developing Alzheimer’s disease. NSAIDs are known to inhibit the actions of cyclo-oxygenases, and the scientists believe that if they can succeed in creating a more powerful compound to block cyclo-oxygenase activity, it could lead to a drug that would actually halt the disease. Current Alzheimer’s drugs treat the symptoms, but no drug has been found yet to stop the progression of Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017
Principal Investigator
Rik Ossenkoppele, PhD
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017

Principal Investigator
Rik Ossenkoppele, PhD
Alzheimer's Disease Research
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022
Principal Investigator
Hyunjun Yang, PhD
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Hyunjun Yang, PhD
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD